-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
It is reported that, as the world's first approved single drug to treat solid tumor antibody drug conjugate (ADC), and the first landing in China antibody conjugate (ADC) class landmark targeted anti-cancer drugs, enmesqual monosarma new mechanism will make the new complementary treatment after the her2 positive early breast cancer patients still residual lesions of the risk of recurrence or death reduced by 50%, which will bring a new risk of recurrence of early breast cancer patients with a new choice of positive treatment.
it is well known that the overall prognosis of HER2-positive breast cancer is poor, but due to the application of quralmon, the survival of HER2-positive breast cancer patients has reached a similar level to that of HER2-negative breast cancer patients.
therefore is essential for HER2-positive breast cancer, anti-HER2 treatment.
her2-positive early breast cancer patients with the use of queratoma zuma in complementary treatment, 10 years later, there are still some HER2-positive early breast cancer patients will recur metastasis.
and the new auxiliary treatment using qural-beads monobifya-and-par-double-target therapy, there are still about 40-60% of patients who did not reach pCR (pathological complete remission), and patients who did not reach pCR after the new auxiliary treatment had a higher risk of recurrence within 5 years than pCR patients, with a small risk even close to 80%.
KATHERINE study offers hope for this segment of patients.
KATHERINE research is a great advance in the field of breast cancer anti-HER2 treatment. "This study proposes a new treatment decision for HER2-positive early breast cancer patients who still have residual lesions after the new auxiliary treatment," said Professor Lin Ying, deputy director and chief physician of a milk surgery at the First Hospital affiliated with Sun Yat-sen University in
.
KATHERINE study focused on patients who did not reach pCR for the first time, and confirmed the important value of emerytozumab in early herr2-positive breast cancer treatment, adding new milestone evidence and opening up new ideas for the optimal treatment of HER2-positive breast cancer patients.
" Ummetrolzumab has become a turning point in the treatment of herher2 breast cancer, through clever design, the anti-HER2-targeted drug quercetzumab and the inhibitory microtube aggregation of chemotherapy drug medenin through the sulfur ether joint connected into a stable antibody conjugated drug, with target tumor cell killing characteristics, also known as "biological missile", can be positive to HER2 cancer cells directly strong delivery of chemotherapy drugs, and can play a full role in the effect of chemotherapy.
for HER2-positive breast cancer patients who still have residual lesions after the new auxiliary treatment surgery, after using emmetric tobead monotomathetic therapy, can further reduce the risk of disease recurrence and death, and fill the treatment gap for patients with non-pCR HER2-positive breast cancer after the new auxiliary treatment in China. "The use of Emeiqutozumab will greatly enhance patients' confidence in treatment and rehabilitation, and the clinical application of this innovative product will allow more patients and families to see the hope of a cure, while also giving our health care providers a look forward to the treatment and rehabilitation of breast cancer," said Yu Jiajia, deputy director of the nursing department of Fudan University's affiliated Oncology Hospital,
.
" with the launch of Emmettozumab, Roche's three major breast cancer drugs: Herceptin ® (quordal monotagated), ® Oftete (Pactozumab), Hesele ® (Emequiton monotorth), have been established from the initial new auxiliary treatment, postoperative assisted treatment and advanced first-line treatment The anti-HER2 treatment system, in addition to HER2-positive breast cancer, Roche Pharmaceuticals is also in one of the most dangerous breast cancer classification - three-negative breast cancer treatment field, its anti-PD-L1 tumor immunotherapy drug atlizumab, as the world's first treatment of three-negative breast cancer tumor immunotherapy drug has been approved by the FDA.
original title: China's first anti-HER2 anti-body conjugate products listed in China.